

Pharmaceutical and Therapeutics (P&T) Committee

P & T Committee Meeting November 21, 2024

Hybrid Meeting

Location: Grimes State Office Building Room B100 **Time:** 9:30 a.m. – 4:30 p.m.
400 E 14th Street
Des Moines, IA 50319

Virtual Option: Zoom

[https://urldefense.com/v3/https://www.zoomgov.com/j/1609838739?pwd=vQtVpFww7F6OTk8zta4ocVxQydICzB.1_!!IqUcNYopQPk7!IONjQtKmTRxd9XwpMH2RfIozqrqPF3XEiFuHn4kjHR7BreQxoKiXPY70j4OrB6TbqOjRo5RxVle bG_xz1D_IU5g\\$](https://urldefense.com/v3/https://www.zoomgov.com/j/1609838739?pwd=vQtVpFww7F6OTk8zta4ocVxQydICzB.1_!!IqUcNYopQPk7!IONjQtKmTRxd9XwpMH2RfIozqrqPF3XEiFuHn4kjHR7BreQxoKiXPY70j4OrB6TbqOjRo5RxVle bG_xz1D_IU5g$)

Meeting ID: 160 983 8739
Passcode: 621201

Final Agenda

1. Welcome & Introductions
 - a) Committee Members and Staff
2. Committee Business
 - a) Approval of the open session minutes
 - b) Review and approval of updated Policies and Procedures
 - c) Conflict of Interest Disclosure
3. Update
 - a) Preferred Drug List (PDL) – Reference Iowa Medicaid PDL Revision Notifications
 - b) Medicaid Drug Rebate Issues
 - c) Prior Authorization Criteria/Pro-DUR edits – Reference Informational Letters and DUR Recommendations
 - d) Legislation
 - e) Iowa Medicaid Updates
4. Public Comment (**See attachment 1 for Conflict of Interest Disclosure**)
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Must indicate if will be virtual or in-person testimony. Five (5) minute maximum limit.
 - Written - Must submit written comments and a completed conflict of interest disclosure.
 - **All submissions must be received no later than 4:00 p.m. CT November 14, 2024.**
 - Send to pba_iapdinfo@optum.com. **Indicate in email if providing written or verbal comment.**

5. Closed Executive Session - *Motion to go into closed session pursuant to Iowa Code section 21.5(1)(a), to review and discuss closed-session items which are required or authorized by federal law to be kept confidential.*
 - a) Approval of the closed session minutes
 - b) Confidential Economic Review of the Iowa Medicaid PDL, Newly Released Drugs, Newly Released Generic Drugs, New Dosage Forms, and Contracts
 - c) Review and discussion of the Confidential Public Comments

RETURN TO OPEN SESSION

6. PDL discussion and deliberation
(See attachment 2 and 3 for order of discussion)
7. Final Recommendations by the P & T Committee on the Iowa Medicaid PDL (Open Session)
8. Review of Newly Released Drugs
(See attachment 4 for order of discussion)
9. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)
10. Review of Newly Released Generic Drugs, Dosage Forms or Strengths
(See attachment 5 for order of discussion)
11. Final Recommendations by the P & T Committee on Newly Released Generic Drugs, Dosage Forms or Strengths (Open Session)
12. Preview of next meeting
13. Adjournment

Disclaimer: Closed Executive Sessions may be necessary during the deliberation process

[Iowa Medicaid Pharmacy](#)

Next scheduled meeting: April 17, 2025 9:30am - 2:30pm

For more information contact Erin Halverson at erin.halverson@hhs.iowa.gov or (515) 974-3126

Attachment 1

**Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee
Public Comment Conflict of Interest Disclosure**

The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons speaking or providing written comment to the Iowa Medicaid P&T Committee are asked to disclose to the Committee any financial or other affiliation with organizations that may have a direct or indirect interest in the business. Those persons providing public comment to the P&T Committee meetings are asked to disclose potential conflicts on this form. P&T Committee members disclose potential conflicts each year on a separate form.

A financial interest may include, but is not limited to, being a shareholder in the organization, being on retainer with the organization, having research or honoraria paid by the organization, or receiving other forms of remuneration from an organization. An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such financial relationships or affiliation does not necessarily constitute a conflict of interest and will not preclude an individual from participating or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Please indicate type of public comment:

- Verbal Comment** **Written Comment**

Your responses below will be read out loud before your verbal presentation or supplied with your written comment to the P&T Committee.

Please check the box of the statement that best applies.

Statement of No Conflicts

I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.

Disclosures

I do have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee

I refuse to state my affiliation(s)

Organization (List additional on the back of the form.)	Role/Relationship (List additional on the back of the form.)

(print name)

(signature)

(date)

Attachment 2

Iowa Medicaid Preferred Drug List

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

- 1) ACE and Thiazide Combo's
- 2) ACE Inhibitors
- 3) ACE Inhibitors and CA Channel Blockers
- 4) Achondroplasia Treatments
- 5) Acne Products: Isotretinoin
- 6) Agents for Fabry's Disease
- 7) Agents for Gaucher Disease
- 8) Agents for Pheochromocytoma
- 9) Alcohol Deterrents
- 10) Allergenic Extracts
- 11) Alpha-Proteinase Inhibitor
- 12) ALS Drug
- 13) Alzheimer – Cholinomimetics
- 14) Amino Glycosides
- 15) Amyloidosis Treatments
- 16) Analgesics – Misc.
- 17) Anaphylaxis Therapy
- 18) Androgens / Anabolics
- 19) Androgens-Topical
- 20) Anorectal – Misc.
- 21) Anthelmintics
- 22) Anti-Infective Combo's – Misc.
- 23) Antianginals
- 24) Antianginals – Isosorbide Nitrate
- 25) Antiarrhythmics
- 26) Antiasthmatic – 5-Lipoxygenase Inhibitors
- 27) Antiasthmatic – Adrenergic Combos
- 28) Antiasthmatic – Anti-Cholinergics
- 29) Antiasthmatic – Anti-Inflammatory Agents
- 30) Antiasthmatic – Beta-Adrenergics
- 31) Antiasthmatic – Leukotriene Receptor Antagonists
- 32) Antiasthmatic – Misc. Respiratory Inhalants
- 33) Antiasthmatic – Mixed Adrenergics
- 34) Antiasthmatic – Mucolytics
- 35) Antiasthmatic – Nasal Misc.
- 36) Antiasthmatic – Steroid Inhalants
- 37) Antiasthmatic – Xanthines
- 38) Antibiotics – Misc.
- 39) Anti-Cataleptic Agents
- 40) Anticoagulants
- 41) Anticonvulsants
- 42) Antidepressants- MAO Inhibitors
- 43) Antidepressants- Selected SSRI'S
- 44) Antidepressants- SNRI's

- 45) Antidepressants- Tri-Cyclics
- 46) Antidepressants- MISC
- 47) Antidepressants- Serotonin Modulators
- 48) Antidotes
- 49) Antidotes – Chelating Agents
- 50) Antiemetic – 5-HT₃ Receptor Antagonists/Substance P Neurokinin
- 51) Antiemetic – Anticholinergic / Dopaminergic
- 52) Antiemetic – Tetrahydrocannabinol (THC) Derivatives
- 53) Antifungals – Assorted
- 54) Antihemophilia Factor IX Agents
- 55) Antihemophilia Factor VII Agents
- 56) Antihemophilia Factor VIII Agents
- 57) Antihemophilia Factor VonWillebrand Agents
- 58) Antihemophilia Factor X Agents
- 59) Antihistamines – Non-Sedating
- 60) Antihistamines – Non-Sedating / Decongestants
- 61) Antihistamines – Other
- 62) Antihyperlipidemics
- 63) Antihypertensives – Central
- 64) Anti-IGE & Interleukin Antibodies
- 65) Anti-Inflammatories, Non-NSAID
- 66) Antileprotic
- 67) Antimalarial Agents
- 68) Antimycobacterials / Antituberculosis
- 69) Anti-Parkinsonian Drugs
- 70) Antiprotozoal Agents
- 71) Anti-Psoriatics – Non-Biologicals
- 72) Antipsychotics- Atypicals
- 73) Antipsychotics- Special Atypicals
- 74) Antipsychotics- Typical
- 75) Antispasmodics
- 76) Antispasmodics – Long Acting
- 77) Anti-Thrombocytopenics
- 78) Antithyroid Therapies
- 79) Anxiolytics-Benzodiazepines
- 80) Anxiolytics- Long Acting
- 81) Anxiolytics- Misc.
- 82) ARB Combinations
- 83) ARB/CCB
- 84) ARB/CCB Plus Diuretics
- 85) ARB's
- 86) ARB's and Diuretics
- 87) Arthritis – Misc.
- 88) Artificial Saliva / Stimulants
- 89) Atopic Dermatitis
- 90) Beta Blockers – Alpha / Beta
- 91) Beta Blockers – Cardio Selective
- 92) Beta Blockers – Non-Selective
- 93) Beta Blockers and Diuretic Combo's
- 94) Beta – Lactams / Clavulanate Combo's
- 95) BPH
- 96) Calcium Channel Blockers – Amlodipines
- 97) Calcium Channel Blockers – Diltiazems
- 98) Calcium Channel Blockers – Felodipines
- 99) Calcium Channel Blockers – Isradipines
- 100) Calcium Channel Blockers – Nifedipines
- 101) Calcium Channel Blockers – Nisoldipine

- 102) Calcium Channel Blockers – Verapamils
- 103) Carbapenems
- 104) Cardiac Glycosides
- 105) Cardiovascular Agents
- 106) Carnitine Replenisher – Agents
- 107) CCB / Lipid
- 108) Central Nervous System Agents
- 109) Cephalosporins
- 110) CGRP Inhibitors
- 111) Chelating Agents
- 112) Cholesterol – Bile Sequestrants
- 113) Cholesterol – Fibric Acid Derivatives
- 114) Cholesterol – HMG COA + Absorb Inhibitors
- 115) Cholesterol – HMG COA + Absorb Inhibitors: High Potency Drugs/Combinations
- 116) Cholesterol – HMG COA + Absorb Inhibitors: Low Potency Drugs/Combinations
- 117) Cholinergic
- 118) Complement Inhibitors
- 119) Compounding Materials
- 120) Contraceptives – Emergency Contraceptives
- 121) Contraceptives – Injectable
- 122) Contraceptives – Monophasic Combination O/C's
- 123) Contraceptives – Multi-Phasic Combinations
- 124) Contraceptives – Patches / Vaginal Products
- 125) Contraceptives – Progestin Only
- 126) Contraceptives – Tri-Phasic Combinations
- 127) Cough / Cold – Antitussive – Expectorant
- 128) Cough / Cold – Systemic Decongestants
- 129) COVID-19 Agents
- 130) Cox 2 Inhibitors – Selective
- 131) Cushings Disease Treatments
- 132) Cystic Fibrosis Agents
- 133) Cyto-Megalovirus Agents
- 134) Dental Products
- 135) Diabetic – AlphaglucoSIDase
- 136) Diabetic – Insulin
- 137) Diabetic – Insulin Penfills
- 138) Diabetic – Meglitinides
- 139) Diabetic – Non-Insulin Injectables
- 140) Diabetic – Oral Biguanides
- 141) Diabetic – Oral Sulfonylureas
- 142) Diabetic – Other
- 143) Diabetic – Sulfonylurea / Biguanide
- 144) Diabetic – Thiazol
- 145) Diabetic – Thiazol / Biguanide Combo
- 146) Diabetic Amylin Analogs
- 147) Diabetic- DPP-4 Inhibitor Combinations
- 148) Diabetic- GIP/GLP-I Receptor Agonists
- 149) Diabetic- GLP-I Receptor Agonists
- 150) Diabetic- Insulin Combinations
- 151) Diabetic- SGLT2 Inhibitor Combinations
- 152) Diabetic- Sodium-Glucose Co-Transporter (SGLT2) Inhibitors
- 153) Direct Renin Inhibitors
- 154) Diuretics
- 155) Dopamine Receptor Agonists
- 156) Ear
- 157) Electrolytes / Nutritional
- 158) Endocrine Metabolic Agents

- 159) Endometriosis Agents
- 160) Endothelin and Angiotensin II Receptor Agonists
- 161) Erythropoiesis Stimulating Agents
- 162) Estrogen Combo's
- 163) Estrogens – Patches
- 164) Estrogens – Tabs
- 165) Fluoroquinolones
- 166) GI – Anti-Flatulents / GI Stimulants
- 167) GI – Antidiarrheal / Antacid – Misc.
- 168) GI – Antiperistaltic Agents
- 169) GI – Digestive Enzymes
- 170) GI – H2-Antagonists
- 171) GI – Inflammatory Bowel Agents
- 172) GI – Irritable Bowel Syndrome Agents
- 173) GI – Misc.
- 174) GI – Misc. Anti-Ulcer
- 175) GI – Prostaglandins
- 176) GI – Proton Pump Inhibitor
- 177) GI – Proton Pump Inhibitor / NSAID Combo
- 178) GI – Ulcer Anti-Infective
- 179) GI, Constipation-IBS-OIC
- 180) Glucocorticoids – Corticotropin
- 181) Glucocorticoids – Mineralocorticoids
- 182) Gout
- 183) Granulocyte CSF
- 184) Growth Hormone
- 185) Heart Failure Agents
- 186) Hemostatic
- 187) Hepatitis B Only
- 188) Hepatitis C Agents
- 189) Hereditary Angioedema Agents
- 190) Hereditary Tyrosinemia Type I (HT-I) Treatment – Agents
- 191) Herpes Agents
- 192) Hormone Receptor Modulators
- 193) Hyperparathyroid Treatment – Vitamin D Analogs
- 194) Hyperparathyroid Treatment – Vitamin D Analogs and Calcimimetics
- 195) Idiopathic Pulmonary Fibrosis
- 196) Immune Serums
- 197) Immunosuppressants
- 198) Influenza Agents
- 199) Interferon Gamma
- 200) K Removing Resins
- 201) Lincosamides / Oxazolidinones / Leprostatics
- 202) Lipodystrophy Agents
- 203) Lithium
- 204) Macrolides / Erythromycin's / Ketolides
- 205) Migraine – Ergotamine Combinations
- 206) Migraine – Ergotamine Derivatives
- 207) Migraine – Selective Serotonin Agonists (5HT) – Injectables
- 208) Migraine – Selective Serotonin Agonists (5HT) – Tabs
- 209) Migraine-Selective Serotonin Agonist-(5HT) Combinations
- 210) Mineralocorticoid – Receptor Antagonists
- 211) Minerals
- 212) Mouth – Anesthetics Topical Oral
- 213) Mouth – Steroids
- 214) Mouth Anti-Infectives
- 215) Mouth Antiseptics

- 216) Multiple Sclerosis Agents
- 217) Multiple Sclerosis Agents-Interferons
- 218) Multiple Sclerosis Agents-Non-Interferons
- 219) Muscle Relaxants
- 220) Muscular Atrophy Agents
- 221) Narcotic – Antagonists
- 222) Narcotics – Selected
- 223) Narcotics – Long Acting
- 224) Nasal Steroid/Antihistamine Combos
- 225) Nasal Steroids
- 226) Neurologics – Misc.
- 227) Nicardipines
- 228) Nicotine Replacement Therapy
- 229) Nitro – Ointment / Cap / CR
- 230) Nitro – Patches
- 231) Nitro – Sublingual / Spray
- 232) NSAIDS
- 233) Op. Antiallergics-Antihistamines
- 234) Op. Antiallergics-Mast Cell Stabilizers
- 235) Op. Antibiotics
- 236) Op. Antiinflammatory / Steroids Ophth
- 237) Op. Beta-Blockers
- 238) Op. Carbonic Anhydrase Inhibitors / Combo
- 239) Op. Cycloplegics
- 240) Op. Miotics – Direct Acting
- 241) Op. Misc.
- 242) Op. NSAID's
- 243) Op. Prostaglandins
- 244) Op. Quinolones
- 245) Op. Quinolones-Fourth Generation
- 246) Op. Rho Kinase Inhibitors
- 247) Op. Selective Alpha Adrenergic Agonists
- 248) Opioid Withdrawal Treatments
- 249) Osteoporosis
- 250) Oxytocics
- 251) Parkinsons – Anticholinergics
- 252) Parkinsons – COMT Inhibitors
- 253) Parkinsons – Selected Dopamine Agonists
- 254) Phenylketonuria
- 255) Phosphate Binders
- 256) Phosphodiesterase Inhibitors
- 257) Platelet Aggr. Inhibitors / Combo's – Misc.
- 258) Platelet Aggregation Inhibitors
- 259) Powders
- 260) Pressors
- 261) Progeria Treatments
- 262) Progestins
- 263) Psychotherapeutic Combination
- 264) Pulmonary Anti-Hypertensives
- 265) Pulmonary Anti-Hypertensives-Endothelin Receptor Antagonist
- 266) Purine Analog
- 267) Pyruvate Kinase Activators
- 268) Restless Leg Syndrome Agents
- 269) Rheumatoid Arthritis – Non-Biologicals
- 270) RSV Agents
- 271) Sedative / Hypnotics – Barbiturate
- 272) Sedative / Hypnotics – Benzodiazepines

- 273) Sedative / Hypnotics – Non-Benzodiazepines
- 274) SGLT 1/2 Inhibitors
- 275) Sickle Cell Anemia Agents
- 276) Sinus Node Inhibitors
- 277) SLE Agents
- 278) Smoking Cessation (Oral)
- 279) Somatostatic Agents
- 280) Stimulants
- 281) Stimulants- Amphetamines- Long Acting
- 282) Stimulants- Amphetamines- Short Acting
- 283) Stimulants- Methylphenidate
- 284) Stimulants- Methylphenidate- Long Acting
- 285) Stimulants- Other Stimulants/ Like Stimulants
- 286) Tetracyclines
- 287) Thyroid Hormones
- 288) Tissue Plasminogen Activator
- 289) Topical – Acne Preparations
- 290) Topical – Antibiotic
- 291) Topical – Antifungals
- 292) Topical – Antineoplastics
- 293) Topical – Antipruritics
- 294) Topical – Antiseborrheics
- 295) Topical – Antivirals
- 296) Topical – Astringents / Protectants
- 297) Topical – Burn Products
- 298) Topical – Cauterizing Agents
- 299) Topical – Corticosteroids-High Potency
- 300) Topical – Corticosteroids-Low Potency
- 301) Topical – Corticosteroids-Medium Potency
- 302) Topical – Emollients
- 303) Topical – Enzymes / Keratolytics / Urea
- 304) Topical – Genital Warts
- 305) Topical – Immunomodulators
- 306) Topical – Local Anesthetics
- 307) Topical – Scabicides and Pediculicides
- 308) Topical – Steroid Combinations
- 309) Topical – Steroid Local Anesthetics
- 310) Topical – Tretinoids
- 311) Topical-Wound/Decubitus Care
- 312) Urea Cycle Disorder – Agents
- 313) Urological – Misc.
- 314) Vaginal – Antifungals
- 315) Vaginal – Antibacterials
- 316) Vaginal – Estrogens
- 317) Vasopressins
- 318) Vitamins
- 319) Vitamins – Misc.

Attachment 3
Iowa Medicaid Preferred Drug List Changes

The below changes are recommended to maximize cost savings to the program, unless otherwise noted:

1. Levalbuterol nebulization solution to Preferred
2. Asmanex HFA to Preferred
3. Clonazepam ODT to Preferred
4. Lamotrigine ER Tablets to Preferred
5. Levetiracetam ER Tablets to Preferred
6. Epidiolex to Preferred with 12 month electronic lookback for 2 antiepileptic drugs
7. Citalopram 30mg capsules to Non-Preferred
8. Paroxetine oral suspension to Non-Preferred
9. Venlafaxine ER Tablets to Preferred
10. Amoxapine to Non-Preferred
11. Rebinyn to Preferred
12. Eloctate to Preferred
13. Altuviiio to Preferred
14. Adbry to Preferred with Conditions
15. Amjevita 40mg/0.4 mL and 80mg/0.8mL to Preferred with Conditions
16. Yusimry to Preferred with Conditions
17. Adalimumab-fkjp to Preferred with Conditions
18. Tremfya to Preferred with Conditions
19. Skyrizi Subcutaneous (Prefilled Syringe, Auto-Injector, Solution Cartridge) to Preferred with Conditions
20. Rinvoq to Preferred with Conditions
21. Adalimumab-aacf to Preferred with Conditions
22. Adalimumab-adbm to Preferred with Conditions
23. Uzedy to Preferred Step 2
24. Rykindo to Preferred Step 2
25. Tolterodine Tablets to Preferred
26. Myrbetriq Tablets to Preferred
27. Tolterodine ER Capsules to Preferred
28. Opzelura to Preferred with Conditions
29. Hemangeol to Preferred with PA for diagnosis confirmation
30. Felodipine to Preferred
31. Verapamil ER Capsules to Preferred
32. Carnitor tablets to Non-Preferred
33. Levocarnitine tablets to Preferred

34. Ubrelvy to Preferred with Conditions
35. Colestipol Oral Granules & Packet to Non-Preferred
36. Prevalite to Preferred
37. Zafemy to Preferred
38. Novolin N FlexPen to Preferred
39. Novolin R FlexPen to Preferred
40. Invokana to Non-Preferred with Conditions
41. Invokamet to Non-Preferred with Conditions
42. Dermotic to Non-Preferred
43. Fluocinolone Acetonide Otic to Preferred
44. Veozah to Preferred
45. Mircera to Preferred with Conditions
46. Retacrit to Non-Preferred with Conditions
47. Bijuva to Preferred
48. Duavee to Preferred
49. Suflave to Preferred
50. Gavilyte-C to Preferred
51. Pertzye to Preferred
52. Emflaza to Preferred with Conditions
53. Fylnetra to Non-Preferred with Conditions
54. Fulphila to Preferred with Conditions
55. Sodium polystyrene sulfonate oral powder to Non-Preferred due to risk of adverse events
56. Frovatriptan to Preferred with Conditions
57. Eletriptan to Preferred with Conditions
58. Kesimpta to Preferred
59. Copaxone 20mg/mL to Non-Preferred
60. Zimhi to Preferred
61. Xiidra to Preferred
62. Procentra to Preferred with Conditions
63. Focalin XR to Preferred with Conditions
64. Armour Thyroid to Preferred
65. Niva Thyroid to Preferred
66. NP Thyroid to Preferred
67. Carbaglu to Preferred with PA
68. Xaciato Gel to Preferred
69. Vandazole to Preferred

Attachment 4
Newly Released Drugs

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Iqirvo- Recommend status on the PDL as Non-Preferred
2. Lazcluze- Recommend status on the RDL as Non-Recommended with Conditions ([Select Oncology Agents](#))
3. Livdelzi- Recommend status on the PDL as Non-Preferred
4. Ohtuvayre- Recommend status on the PDL as Non-Preferred
5. Tryvio- Recommend status on the PDL as Non-Preferred
6. Voranigo- Recommend status on the RDL as Non-Recommended with Conditions ([Select Oncology Agents](#))
7. Xolremdi- Recommend status on the PDL as Non-Preferred

Attachment 5

Newly Released Generic Drugs, New Dosage Forms, New Drug Names, New Drug Strengths

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

NEWLY RELEASED GENERIC DRUGS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Dasatinib	Sprycel / Preferred with Conditions	Non-Preferred with Conditions
Ivabradine	Corlanor / Non-Preferred with Conditions	Non-Preferred with Conditions
L-glutamine	Endari / Non-Preferred	Non-Preferred
Liraglutide	Victoza / Preferred with Conditions	Non-Preferred with Conditions
Lofexidine	Lucemyra / Non-Preferred	Non-Preferred
Oxcarbazepine ER	Oxtellar XR / Non-Preferred with Conditions	Non-Preferred with Conditions

NEW DRUG DOSAGE FORMS/STRENGTHS/COMBINATIONS/BIOSIMILARS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Adalimumab-aaty	Yuflyma / Non-Preferred with Conditions	Non-Preferred with Conditions
Crexont	Carbidopa-Levodopa Tabs / Preferred	Non-Preferred with Conditions
Entresto Sprinkle Caps	Entresto Tabs / Preferred	Non-Preferred with Conditions
Onyda XR	Clonidine ER Tabs / Preferred	Non-Preferred
Simlandi	Humira / Preferred with Conditions	Preferred with Conditions
Sitagliptin / Metformin	Janumet / Preferred	Non-Preferred with Conditions
Tyenne Subcutaneous Solution (Auto-Injector & Prefilled Syringe)	Actemra / Non-Preferred with Conditions	Preferred with Conditions
Vigafyde	Vigabatrin / Non-Preferred	Non-Preferred